Open – 2027

EP PerMed - CGT4PM2027 - Cell and Gene Therapy for Personalised Medicine

In the frame of the European Partnership for Personalised Medicine, EP PerMed, (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), the French National Research Agency (ANR), in collaboration with 37 funding organisations, launches a joint transnational call for proposals on “Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)”. The available budget for this call is over 38 Mio€.

The following countries (24) are participating in the preparation of the call: Austria, Belgium, Canada, Czech Republic, Estonia, Finland, France, Germany, Hungary, Ireland, Israel*, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovak Republic, Spain, Sweden, The Netherlands and Türkiye (contact list is provided below).

Five of the participating countries are represented by their specific regions (10): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Wallonia (Belgium), Saxony (Germany), Friuli-Venezia Giulia (Italy), Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Andalusia (Spain), and Catalonia (Spain). * Decision on participation is still pending.

The JTC2027 will fund research projects in human health on Cell and Gene Therapy (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM.

At least one of the following approaches must be employed:

  • Somatic cell therapeutics (e.g., in the form of stem cells, organoids, or cells of the immune system);
  • Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing;
  • Combined cell- and gene therapeutics in the form of genetically modified cells;
  • Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.

Research projects in all disease areas are encouraged

Clinical trials (phases I-IV), defined as prospective interventional clinical studies involving the administration of an investigational medicinal product in human subjects, are excluded and will not be funded. Refer to the “Call Text” for the exhaustive list exclusions.

Only transnational projects will be funded.

ANR will only fund the French partners of the selected projects. In agreement with ANR policy, funded researchers should respect the guidelines of the Nagoya protocol and consider open access publication of their results.

Open
Closed
Opening : 2026-11-16 at 09:00 CET
Deadline for pre-proposals submission : 2027-01-20 at 14:00 CET
Deadline for full proposals submission : 2027-05-25 at 14:00 CEST

The call will be implemented in two stages, i.e. a pre- and a full proposal phase.

The eligibility criteria and rules regarding the consortium composition are outlined in the Call Text.

The Call Text, Guidelines for Applicants, and the Application Form are available on the JTC2027 webpage.

The completed scientific application must be submitted on the electronic proposal submission tool PT-Outline (no proposals will be accepted by ANR directly).

At the full proposal stage, partners requesting funding from ANR will be asked to follow a parallel submission procedure on the ANR submission platform.

The EP PerMed Joint Call Secretariat (JCS):

The French National Research Agency

Mylène Vaillancourt, Dr. Mérick Machouri
Phone: +33 1 78 09 80 36, +33 1 72 73 06 72
Email: EPPerMed(at)anr.fr

InstrumentsFinancements

Consult the upcoming and current calls of the appelsprojetsrecherche.fr portal


The appelsprojetsrecherche.fr portal centralises all information on calls for proposals and calls for applications from ADEME, ANR, Inserm including ANRS, Anses and INCa. It provides a simplified access to upcoming and ongoing calls, giving a greater visibility to funding opportunities. Following their closing date, the calls remain published for a few months.

Portail appelsprojetsrecherche.fr

Sign up for the latest news:
Subscribe to our newsletter